非小细胞肺癌患者血清血管内皮生长因子受体2和内皮抑素与临床特征的相关性研究

摘要

目的:探究非小细胞肺癌患者外周血血管内皮生长因子受体2(vascular endothelial growth factor receptor 2,VEGFR-2)和内皮抑素(endostatin,ES)与临床特征的相关性及其意义.方法:选取2009年在上海市第六人民医院心胸外科接受手术治疗的38例非小细胞肺癌(non-small cell lung cancer,NSCLC)患者,用ELISA法检测其术前血清VEGFR-2、ES水平,分析二者相关性,并分析它们与年龄、性别、病理类型、肿瘤最大直径、肿瘤内血管密度(micro vessel density,MVD)、临床分期相关性及意义.结果:患者血清ES水平为(20.29±6.10)μg/L,VEGFR-2水平为(7.42±4.28)μg/L,ES表达水平与VEGFR-2表达水平无明显相关性(P＞0.05),ES与肺癌病灶内MVD呈直线负相关关系(r=-0.867,r2=0.752),直线回归方程为Y=32.002-0.499X(μg/L)(P＜0.001);ES、VEGFR-2表达水平与其他临床特征无明显相关性(P＞0.05).结论:胸外科NSCLC患者外周血ES水平可能影响肺癌病灶内肿瘤内血管密度,从而影响肿瘤的生长,VEGFR-2、ES可能无法单独作为接受手术治疗NSCLC患者分期及预后判断的有效指标.%Objective: To study the relationship between clinical significance and the serum levels of vascular endothelial growth factor receptor 2 (VEGFR-2), endostatin (ES) in patients with non-small cell lung cancer (NSCLC). Methods: The serum VEGFR-2, ES levels were detected by ELISA method in 38 patients with NSCLC in Shanghai 6th People's Hospital cardiothoracic surgery department in 2009. The correlations were analyzed among VEGFR-2, ES and the clinical characters, age, sex, pathology, diameter of tumor, clinical stage, micro vessel density (MVD) of tumor. Results: The serum level of ES [(20.29±6.10) μg/L] was uncorrelated with that of VEGFR-2 [(7.42 ±4.28) μg/L] (P>0.05); the serum level of ES was correlated with MVD of tumor (r= -0.867, r2=0.752), the linear regression equation was [Y=32.002-0.499X (μg/L)] (P<0.001); ES and VEGFR2 were uncorrelated with the other clinical characters. Conclusion: The serum level of ES may change the MVD of tumor, ES, VEGFR-2 and the clinical characters are uncorrelated in NSCLC patients. It suggests that VEGFR-2 and ES may be failed to be used as effective markers to predict stages and prognosis in NSCLC patients.